Phase 2
Completed N=91
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Source: ClinicalTrials.gov NCT06164743 ↗Enrolled (actual)
91
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Anterior Chamber Cell: Categorical Cure — 18; 16; 6 Participants
Summary
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Anterior Chamber Cell: Categorical Cure |
18; 16; 6 | — |
| SECONDARY Safety of VVN461 |
2; 3; 3 | — |
Eligibility Criteria
Inclusion Criteria
- ≥21 years of age and in good general health at Visit 1 (Screening)
- Willing and able to provide informed consent and provide relevant privacy authorization(s)
- Willing and able to comply with study requirements and visit schedule
- Clear ocular media (other than cataract) in the study eye
- Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens.
Exclusion Criteria
- Any ocular pain at Visit 1 (Screening)
- Recent use of corticosteroids or oral non-steroidal anti-inflammatory drugs
Data sourced from ClinicalTrials.gov (NCT06164743). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.